Abstract: The invention provides compounds of Formula I: wherein b, D, R1, R2, G, Ra and Rb have meanings given in the description, or pharmaceutically-acceptable salts or solvates, or pharmaceutically functional derivatives thereof. The invention further provides process for conjugating the compounds to carrier molecules and uses of such compounds and conjugates in the treatment of disease.

Abstract: The invention provides a compound comprising a photosensitizing agent coupled to a carrier molecule with a minimum coupling ratio of 3:1 wherein the carrier molecule has a binding specificity for a target cell. There is also provided a process of conjugation comprising the use of a first and second aprotic solvent and uses of the conjugated compounds.

Abstract: The invention provides compounds of Formula (I): wherein b, D, R1, R2, G, Ra and Rb have meanings given in the description, or pharmaceutically-acceptable salts or solvates, or pharmaceutically functional derivatives thereof. The invention further provides process for conjugating the compounds to carrier molecules and uses of such compounds and conjugates in the treatment of disease.

Abstract: The invention relates to the modification of proteins to improve their, biochemical, immunological or biophysical properties, in turn leading to such proteins having increased diagnostic, biotechnological or therapeutic benefit. In particular the invention relates to polysialylation of proteins or conjugates of proteins. There is also provided, nucleotide sequences and expression vectors encoding, host cells expressing, compositions comprising and uses of the polysialylated molecules of the invention.

Abstract: FR1 ?????????1?????????2?????????3 H1-H2 Locus 123456789012345678901234567890 VH1 1-3 1-02 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-3 1-03 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-3 1-08 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-2 1-18 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-U 1-24 QVQLVQSGAEVKKPGASVKVSCKVSGYTLT 1-3 1-45 QMQLVQSGAEVKKTGSSVKVSCKASGYTFT 1-3 1-46 QVQLVQSGAEVKKPGASVKVSCKASGYTFT 1-3 1-58 QMQLVQSGPEVKKPGTSVKVSCKASGFTFT 1-2 1-69 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS 1-2 1-e QVQLVQSGAEVKKPGSSVKVSCKASGGTFS 1-2 1-f EVQLVQSGAEVKKPGATVKISCKVSGYTFT VH2 3-1/2-1 2-05 QITLKESGPTLVKPTQTLTLTCTFSGFSLS 3-1 2-26 QVTLKESGPVLVKPTETLTLTCTVSGFSLS 3-1 2-70 QVTLKESGPALVKPTQTLTLTCTFSCFSLS VH3 1-3 3-07 EVQLVESGGGLVQPGGSLRLSCAASGFTFS 1-3 3-09 EVQLVESGGGLVQPGRSLRLSCAASGFTFD 1-3 3-11 QVQLVESGGGLVKPGGSLRLSCAASGFTFS 1-1 3-13 EVQLVESGGSLVQPGGSLRLSCAASGFTFS 1-U 3-15 EVQLVESGGGLVKPGGSLRLSCAASGFT

Abstract: The invention relates to a library, methods of making a library of biologically active molecules and uses thereof. The library comprises a plurality of chelating ligand pairs, each said ligand pair including two ligands that bind specifically to distinct epitopes on the same target molecule and the two ligands of each ligand pair being joined by a linker, wherein the members of the library comprise linkers of variable length and variable amino acid composition.

Abstract: The present invention relates to a polypeptide comprising at least one alpha-helix having synthetically attached thereto a plurality of therapeutic or diagnostic moieties, wherein said therapeutic or diagnostic moieties may be the same or different and are spatially oriented on the polypeptide so as to minimise interactions between said moieties. Further aspects of the invention relate to a pharmaceutical composition comprising the polypeptide; a polynucleotide sequence encoding the polypeptide; an expression vector comprising said polynucleotide sequence; and a host cell transformed with said expression vector. The invention also provides a method of treatment comprising administering to a subject in need thereof a therapeutically effective amount of said polypeptide.

Abstract: Fusion compounds comprising a target cell-specific portion fused to an oligomeric rival nuclease are disclosed. The inventive compounds are useful as anti-cancer agents. Methods of preparation and use of the inventive compounds are disclosed.